BD&L Summit · Munich · Germany

BioPharma Deals Conference Europe's Premier Life Sciences Dealmaking Summit

Where biopharma BD&L leaders connect to explore licensing opportunities, establish strategic partnerships and advance transactions.

The BioPharma Deals Conference brings together biopharma BD&L executives, investors and transaction specialists to discuss asset licensing, co-development, M&A and commercial partnerships. Over two days, dedicated partnering meetings and executive discussions provide opportunities to assess portfolio fit, engage prospective partners and advance deal discussions.

24th & 25th November 2026
Munich, Germany
200+ Senior BD&L Leaders
Register Now View Programme
Event at a Glance
BioPharma Deals — BD&L Summit 2026
Dates: 24th & 25th November 2026
Venue: Science Congress Center, Munich
Audience: Pharma · Biotech · Investors · Service & Solution Providers · Platforms
Focus: Licensing Deals · Alliances · M&A · Corporate Partnerships · Co-Development · Out-Sourcing · External Innovation · Investments
Format: Panel discussions · Keynotes · Company Presentations · One to One Meetings
Secure Your Seat →
scroll
BD&L Leaders
Expert Speakers
Intensive Days
European Hub
BioPharma BD&L dealmakers networking BD&L Summit keynote speaker
BD&L Conference
Europe's BD&L Epicentre

Where Pharma Biotech
Deals Get Done

The BioPharma Deals Conference brings together pharmaceutical and biotechnology executives responsible for business development, licensing and external innovation to evaluate partnering opportunities and advance transactions.

The programme centres on the scientific, clinical and commercial considerations that inform asset selection, valuation and deal execution. Focused sessions and dedicated partnering meetings support substantive discussions on licensing, co-development, investment and strategic collaborations aligned with portfolio priorities.

Licensing M&A Co-Development Partnering Capital Raising IP Strategy
Explore the Programme
Why Attend

Sharper Deal Insight
Stronger Negotiating Positions

Gain perspective on licensing economics, partner expectations and negotiation priorities through discussions with experienced BD&L executives, transaction specialists and prospective partners.

Deal Economics & Valuation

Examine how clinical evidence, competitive positioning and remaining development risk influence asset value, upfront payments, milestone economics and royalty provisions.

Bilateral Partnering Meetings

Meet prospective counterparties to establish mutual interest, clarify the scope of available rights and agree next steps for information exchange and asset assessment.

BD&L Executive Perspectives

Hear how senior dealmakers establish acquisition and licensing priorities, assess opportunities against internal investment criteria and secure organisational alignment on proposed transactions.

Asset & Platform Presentations

Present the scientific rationale, supporting data and development pathway behind your assets or platform, with a clear account of differentiation, upcoming milestones and partnering objectives.

Transaction Structuring Masterclasses

Work through practical considerations in licensing and M&A, including diligence findings, territorial rights, development obligations, governance provisions and the negotiation of definitive agreements.

Corporate & Investor Relationships

Build relationships with pharmaceutical executives, biotech leadership and specialist investors, gaining perspective on sourcing mandates, capital requirements and appetite for emerging therapeutic opportunities.

Why BD&L Leaders Choose This Summit

Connecting Scientific
Potential
with Strategic Investment

Translating promising science into medicines requires alignment between asset owners, development partners and capital providers. BD&L brings these interests together through agreements that define rights, responsibilities and the allocation of value.The BioPharma Deals Conference brings biopharma executives and investors together to explore licensing, co-development and investment opportunities, with discussions grounded in development priorities, portfolio strategy and commercial objectives.

Join the Summit
85%
Senior level and above attendees
10+
Therapy areas represented
30+
Countries represented
60%
Return attendance rate
Who Attends

A Room Full of
Decision Makers

01
Chief Business Officers & BD Leaders

Senior executives from global, specialty and emerging pharmaceutical companies directing external innovation, licensing strategy and portfolio expansion.

Business Development · External Innovation
02
Biotech CEOs & Founders

Biotechnology leaders seeking partners and capital to advance pipeline assets, validate technology platforms and support development through commercialisation.

Out-licensing · Strategic Financing
03
Life Sciences Investors

Venture capital, corporate venture and specialist investment teams assessing scientific differentiation, development milestones and financing requirements across companies and therapeutic assets.

Venture Capital · Corporate Investment
04
Licensing & Alliance Management Leaders

Licensing professionals negotiating rights and deal terms, alongside alliance leaders responsible for joint governance, contractual commitments and collaboration performance.

Licensing · Alliance Management
05
M&A & Corporate Development Executives

Corporate development teams evaluating acquisitions, divestments and strategic combinations to address portfolio gaps, secure capabilities and deliver corporate growth objectives.

M&A · Portfolio Strategy
06
Legal, IP & Transaction Advisers

Legal counsel, patent specialists, investment bankers and financial advisers supporting due diligence, valuation, transaction structuring and the negotiation of definitive agreements.

Legal · Intellectual Property · Finance
Conference Experience

Two Days. The Right Partners
Your Next Deal Starts Here

Company Pipeline Pitch
Pipeline Pitch
Expert BD&L Panel
BD&L Panel
1-to-1 Partnering
1:1 Partnering Sessions
Networking
Deal Networking
Innovation Exhibition
Innovation Exhibition
Summit Audience
The BD&L Community

"Transformative biopharma transactions begin where scientific conviction meets strategic intent, bringing complementary portfolios, development capabilities and capital into alignment."

BioPharma Deals Conference